Related Concept Videos
Cancer Survival Analysis
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Nursing Evaluation
Outcome Measurement Instruments Used to Evaluate Dermatologic Adverse Events in Cancer Trials: A Systematic Review.
Sheila Shaigany1,2,3, Nicole Mastacouris1, Rachel Tannenbaum1
1Northwell Health, New Hyde Park, New York.
View abstract on PubMed
Clinician-reported and patient-reported outcome measures for dermatologic adverse events (DAEs) in cancer therapy have limited validity and specificity. Reevaluation of current frameworks is needed to improve the assessment of these common chemotherapy side effects.
More Related Videos
06:21Diffuse Optical Spectroscopy for the Quantitative Assessment of Acute Ionizing Radiation Induced Skin Toxicity Using a Mouse Model
Published on: May 27, 2016
06:31Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response
Published on: October 3, 2019
Area of Science:
- Oncology
- Dermatology
- Clinical Trials
- Health Outcomes Research
Background:
- Dermatologic adverse events (DAEs) are common and impactful side effects of systemic cancer therapy.
- Accurate assessment of DAEs requires validated clinician-reported outcome measures (ClinROMs) and patient-reported outcome measures (PROMs).
- Existing measures often lack specificity and consistency in evaluating mucocutaneous toxic effects.
Conclusions:
- There is a narrow spectrum of ClinROMs and PROMs with limited validity for measuring DAEs in systemic chemotherapy trials.
- The reporting of DAEs in trials often lacks specificity and meaningful interpretation.
- A collaborative reevaluation of frameworks for assessing cutaneous toxic effects in oncology trials is warranted due to existing measurement and reporting gaps.
